It is likely that in the coming years an approach similar to that leading to explore the potential of propranolol in ROP, might be used to extend to preterm infants the results of preclinical studies on the efficacy of β3-AR agonism. The gene discussed is ADRB3; the disease is retinopathy of prematurity.